GLP‑1 receptor agonist
Semaglutide
2 Formats
Targets the GLP‑1 receptor pathway with clinician-guided dosing.
From $149/mo
Explore semaglutideYour weight loss journey, simplified.
GLP-1 medications prescribed by licensed clinicians and delivered straight to your door.
- Licensed clinicians
- Personalized treatment
- Free delivery
GLP‑1 weight‑loss treatments
Two treatments.
Clinician-guided.
Both are available as a weekly injection or a daily oral tablet — prescribed, dose‑titrated, and monitored by a licensed clinician.
GIP + GLP‑1 receptor agonist
Tirzepatide
2 Formats
Targets two receptor pathways with clinician-guided dosing.
From $179/mo
Explore tirzepatideBetter health,
in under
3 minutes.
Your custom plan, from a quick quiz to your front door.
- Assessment
Answer a few questions
A short online intake covering your goals and medical history — no commitment, no obligation.
3 minutes
- Clinical review
A clinician reviews your case
A licensed provider reviews your intake and tailors a protocol — medication, supplementation, and lifestyle.
24 hours
- Delivered
Shipped to your door
Discreet delivery, then ongoing support in the ZenBody app: tracking, coaching, and monthly check‑ins.
2 days
Typical timings — your clinical review time may vary by case.
Clinical research
Understand the evidence.
Published studies examine specific treatment regimens. Results do not predict your individual outcome.
STEP 1
New England Journal of Medicine
68 weeks
Once-Weekly Semaglutide in Adults with Overweight or Obesity
- Studied route
- Subcutaneous injection
- Studied regimen
- 2.4 mg once weekly plus lifestyle intervention
In STEP 1, adults without diabetes receiving 2.4 mg once-weekly subcutaneous semaglutide plus lifestyle intervention had a mean 14.9% body-weight reduction at 68 weeks, versus 2.4% with placebo.
Published studies have evaluated specific semaglutide and tirzepatide regimens. Those results do not establish the effectiveness of Zenbody’s compounded formulations or predict an individual patient’s results.
View published research DOI 10.1056/NEJMoa2032183SURMOUNT-1
New England Journal of Medicine
72 weeks
Tirzepatide Once Weekly for the Treatment of Obesity
- Studied route
- Subcutaneous injection
- Studied regimen
- 5 mg, 10 mg, or 15 mg once weekly plus lifestyle intervention
In SURMOUNT-1, adults without diabetes receiving once-weekly subcutaneous tirzepatide had mean body-weight changes of 15.0%, 19.5%, and 20.9% at 72 weeks at the studied 5 mg, 10 mg, and 15 mg doses.
Published studies have evaluated specific semaglutide and tirzepatide regimens. Those results do not establish the effectiveness of Zenbody’s compounded formulations or predict an individual patient’s results.
View published research DOI 10.1056/NEJMoa2206038
ZenBody® Care
Prescriber-directed GLP-1 care — simplified from start to finish.
ZenBody®
Treatment
options
4options
Prescription required. Eligibility and treatment options vary.
Prescribed Treatment
Selected by a licensed clinician for your care.
Personalized Dose
Tailored to your health profile, goals, and response.
Care that fits your life — and stays with you.
Online care, on your schedule.
100%
+ Clear pricing
Starting monthly
$149+
Personalized treatment with clinical oversight and ongoing support — built around your care.
Specialized pharmacy support
Provider-reviewedPersonalized treatment
Ongoing support
Common questions
FAQSemaglutide is a GLP‑1 receptor agonist; tirzepatide acts on GIP and GLP‑1 receptor pathways. Each is available in injectable and oral compounded formats. Your clinician considers your health history and needs when discussing treatment options.
Injectable compounded formats are taken weekly and require an injection; oral compounded tablets are taken daily. Route, dosing, formulation, and available clinical evidence differ. A clinician determines whether either is appropriate for you.
Your prescribed medication, clinical oversight, progress tracking, shipping, and care-team messaging are included. Your price can change with your prescribed dose.
In many cases, yes. Eligible expenses can often be paid with an FSA or HSA card, and we provide itemized receipts for reimbursement.
Compounded medications are not FDA-approved. FDA does not review compounded medications for safety, effectiveness, or quality before marketing. A licensed clinician determines whether a compounded medication is appropriate for an individual patient.